Icon

OXBRYTA (nda213137)- (300MG,500MG)

VOXELOTOR GLOBAL BLOOD THERAPS
300MG,500MG
Yes No
2037-Oct-12 2024-Nov-25
None None
None No
OXBRYTA is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older.
0 0 0
Total Other Developers 4
Drugs with Suitability No
300MG ** ** - - -
500MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.